Livforsakringsbolaget Skandia, Omsesidigt 13F: Cuts NBIX Stake by $2.6M

Livforsakringsbolaget Skandia cut its stake in Neurocrine Biosciences, Inc. (NBIX) by 18,100 shares during the quarter, ending with 400 shares worth about $56,736, according to a Form 13F filing with the SEC on October 21, 2026. The reduction worked out to a 97.8% decrease from its previous holding of 18,500 shares.

NBIX Neurocrine Biosciences, Inc.

$141.31 ▲ +0.50% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Livforsakringsbolaget Skandia's Neurocrine Biosciences Position

Livforsakringsbolaget Skandia scaled back its investment in Neurocrine Biosciences during the period. The fund previously held 18,500 shares and finished the quarter with just 400 shares remaining, reflecting the sharp 97.8% reduction reported in its latest SEC filing.

Other Institutional Activity in Neurocrine Biosciences

Other large institutional investors adjusted their positions in the drug developer as well. Moody Lynn Lieberson & Walker sold out entirely, cutting its 12,591 shares to zero. Ninety One UK grew its holdings by 434,610 shares, ending with 434,881 shares worth about $61.7 million. Dodge & Cox Inc. grew its holdings by 123,425 shares, ending with 5,584,707 shares worth about $794.7 million. AQR Capital Management, LLC reduced its stake by 1,121,209 shares, ending with 3,818,037 shares worth about $543.3 million. Renaissance Technologies, LLC trimmed its position by 82,967 shares, ending with 2,335,897 shares worth about $332.4 million.

Neurocrine Biosciences, Inc. Stock Up 0.2%

Neurocrine Biosciences shares recently traded around $142.00 as of October 22, 2026. The stock closed at $141.31 on the filing date. It sits below its 50-day moving average of $147.86 and below its 52-week high of $186.12.

Recent Earnings

The company posted $3.37 billion in trailing revenue alongside earnings of $6.82 per share. It generated a net profit margin of 20.9% and a return on equity of 22.1%. The next earnings release is scheduled for November 2, 2026.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Company insiders were active in the stock earlier in the year. Chief Legal Officer Darin Lippoldt bought 200 shares on June 26, 2026, and another 9,800 shares on June 29, 2026. He also sold 9,800 shares under a planned transaction on June 29, 2026.

Analysts Set New Price Targets

Wall Street firms shared updated views on the stock ahead of the filing. On September 8, 2026, RBC Capital reiterated its Outperform rating with a $198.00 price target. Morgan Stanley maintained an Equal-Weight rating with a $183.00 target on September 11, 2026. UBS maintained a Buy rating with a $214.00 target on September 29, 2026. BMO Capital maintained a Market Perform rating with a $150.00 target on October 12, 2026. Needham reiterated a Buy rating with a $204.00 target on October 16, 2026. The stock carries a consensus strong buy rating and a mean target price of $206.54 across 29 analyst opinions.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and commercializes medicines focused on neurological, psychiatric, endocrine, and immunological conditions. Based in San Diego, California, the company markets specialty treatments for patients in the United States and international markets.

Bottom Line

Investors will look toward the upcoming earnings report on November 2, 2026, for fresh guidance on revenue growth and product pipeline updates. Institutional shifts like Skandia's reduction offer a view into how major funds manage risk across large biotechnology holdings.